Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 13, Number 3—March 2007


Intermediate Vancomycin Susceptibility in a Community-associated MRSA Clone

Christopher J. Graber*Comments to Author , Margaret K. Wong*, Heather A. Carleton*, Françoise Perdreau-Remington*, Barbara L. Haller*, and Henry F. Chambers*
Author affiliations: *San Francisco General Hospital, University of California, San Francisco, California, USA;

Main Article


Antimicrobial susceptibility profiles of blood isolate from November 2005, blood isolate from February 2006, and lumbar isolate from April 2006*

Antimicrobial drugMIC (μg/mL) and CLSI interpretation
Nafcillin>2 R16 R>2 R
Clindamycin2 I≤0.25 S<0.25 S
Erythromycin4 I>8 R>4 R
Trimethoprim-sulfamethoxazole<0.5/9.5 S≤0.25/5 S<0.5/9.5 S
Tetracycline<1 S≤0.5 S†<1 S
Rifampin<1 S≤0.25 S<1 S
Ciprofloxacin>2 R>4 R>2 R
Levofloxacin>4 RND>4 R
Gentamicin<1 S≤0.5 S2 S
Vancomycin<2 S2 S8 I
4–6 I‡
DaptomycinND1 S
LinezolidND2 S2 S
TigecyclineND0.125 S0.125 S

*CLSI, Clinical and Laboratory Standards Institute; R, resistant; I, intermediately resistant; S, susceptible; ND, not done.
†Susceptibility to doxycycline performed instead of to tetracycline.
‡Confirmatory susceptibility by E-test and growth on vancomycin (6 µg/mL) agar screen plates.
§Interpreted as nonsusceptible by the Centers for Disease Control and Prevention. Formal CLSI breakpoints for daptomycin resistance have not been established.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO